The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia (CLL) regardless of cytogenetic risk factors, according to 4-year follow-up data being presented the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.1

For the randomized phase 3 RESONATE trial ( Identifier: NCT01578707), researchers evaluated whether ibrutinib — a Bruton’s kinase inhibitor — would improve outcomes over ofatumumab among patients with CLL.

Continue Reading

Of 391 enrolled patients, 195 received ibrutinib and 196 received ofatumumab. At a median 9-month interim analysis, crossover from ofatumumab to ibrutinib was recommended for all patients due to efficacy, though overall survival data for crossover patients were censored.

Median follow-up in the ibrutinib arm was 44 months. The median progression-free survival (PFS) was not reached in the ibrutinib arm vs 8 months in the ofatumumab arm; 3-year PFS was 59% vs 3%, respectively.

The 3-year overall survival rate in the ibrutinib group was 74%. The overall response rate with ibrutinib was 91% with complete responses increasing over time.

Grade 3 or worse adverse events decreased in frequency after 1 year. By 4-year follow up, 39% of patients discontinued ibrutinib for disease progression or adverse events.

RELATED: Durable PFS With Fludarabine, Rituximab, and Lenalidomide in CLL

Ninety of the enrolled patients are still receiving ibrutinib.

Read more of Cancer Therapy Advisor‘s coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.


  1. Byrd JC, Hillmen P, O’Brien SM, et al. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study. J Clin Oncol. 2017;35(suppl; abstr 7510).